Mutations in Two Genes Encoding Different Subunits of a Receptor Signaling Complex Result in an Identical Disease Phenotype
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), also known as "Nasu-Hakola disease," is a globally distributed recessively inherited disease leading to death during the 5th decade of life and is characterized by early-onset progressive dementia and bone cysts. Elsewhere, we have identified PLOSL mutations in TYROBP (DAP12), which codes for a membrane receptor component in natural-killer and myeloid cells, and also have identified genetic heterogeneity in PLOSL, with some patients carrying no mutations in TYROBP. Here we complete the molecular pathology of PLOSL by identifying TREM2 as the second PLOSL gene. TREM2 forms a receptor signaling complex with TYROBP and triggers activation of the immune responses in macrophages and dendritic cells. Patients with PLOSL have no defects in cell-mediated immunity, suggesting a remarkable capacity of the human immune system to compensate for the inactive TYROBP-mediated activation pathway. Our data imply that the TYROBP-mediated signaling pathway plays a significant role in human brain and bone tissue and provide an interesting example of how mutations in two different subunits of a multisubunit receptor complex result in an identical human disease phenotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Homozygous loss-of-function mutations in TREM2 or DAP12 genes cause Nasu–Hakola disease (NHD), a rare genetic disorder characterized by fatal presenile dementia and bone cysts [38, 39].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [39]
In the citing paper
“TYROBP is a transmembrane adaptor protein for TREM2, SIRPβ1, and CR3 receptors, which are known to be involved in AD pathogenesis [90–92].”
From Sex-specific DNA methylation differences in Alzheimer’s disease pathology (2021) · cites this paper as [92]
In the citing paper
“Homozygous Q33X, Y38C and T66M variants have been identified in patients with Nasu-Hakola disease [44, 47, 95].”
From TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation (2021) · cites this paper as [95]
In the citing paper
“A number of mutations in PLCG2 (about 75%), that have been previously implicated in various inflammatory diseases [92–102], actually map to the autoinhibitory interface on the PLCγ2 model structure and can be considered as pathogenic (Fig. 2c)”
From TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation (2021) · cites this paper as [95]
In the citing paper
“Even more rare loss-of-function mutations of TREM2 or DAP12 cause a form of recessively inherited presenile dementia, called Nasu-Hakola disease (126, 127).”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [126]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bouchon, A., Dietrich, J., & Colonna, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.4991 · Cited by 1,284 · cited 4×
“2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather than in acute, inflammation (Bouchon et al. 2000).”
BackgroundInfluentialTREM-1 amplifies inflammation and is a crucial mediator of septic shock
Bouchon, A., Facchetti, F., Weigand, M. A., & Colonna, M. (2001) · Nature · doi:10.1038/35074114 · Cited by 1,090 · cited 2×
“TREM1 is strongly up-regulated in cells that mediate acute inflammatory responses to bacterial infection (i.e., neutrophils and monocytes) (Bouchon et al. 2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather…”
BackgroundImmunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells
Lanier, L. L., Corliss, B. C., Wu, J., Leong, C., & Phillips, J. H. (1998) · Nature · doi:10.1038/35642 · Cited by 904 · cited 5×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundInfluentialVitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2065 · Cited by 748 · cited 1×
“1) (Vitale et al. 1998), MDL1 (chromosome 7q33) (Bakker et al. 1999), CD94 (chromosome 12p13.”
Association of DAP12 with Activating CD94/NKG2C NK Cell Receptors
Lanier, L. L., Corliss, B., Wu, J., & Phillips, J. H. (1998) · Immunity · doi:10.1016/s1074-7613(00)80574-9 · Cited by 559 · cited 5×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundInfluentialLoss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts
Paloneva, J., Kestilä, M., Wu, J., Salminen, A., Böhling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B. H., Phillips, J. H., Pekkarinen, P., et al. (2000) · Nature Genetics · doi:10.1038/77153 · Cited by 460 · cited 6×
“Interestingly, patients with PLOSL who are homozygous for mutations in either TREM2 or TYROBP display identical CNS and bone manifestations (table 2)—and no immunological symptoms (Paloneva et al. 2000).”
BackgroundInfluentialSelf-citationBouchon, A., Hernández-Munain, C., Cella, M., & Colonna, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.8.1111 · Cited by 460 · cited 2×
“TREM1 is strongly up-regulated in cells that mediate acute inflammatory responses to bacterial infection (i.e., neutrophils and monocytes) (Bouchon et al. 2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather…”
BackgroundLy-49D and Ly-49H associate with mouse DAP12 and form activating receptors.
Smith, K. M., Wu, J., Bakker, A. B. H., Phillips, J. H., & Lanier, L. L. (1998) · PubMed · Cited by 277
Cutting Edge: Ly-49D and Ly-49H Associate with Mouse DAP12 and Form Activating Receptors
Smith, K. M., Wu, J., Bakker, A. B. H., Phillips, J. H., & Lanier, L. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.1.7 · Cited by 249 · cited 1×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundMutations in PATCHED-1, the receptor for SONIC HEDGEHOG, are associated with holoprosencephaly
Ming, J. E., Kaupas, M. E., Roessler, E., Brunner, H. G., Golabi, M., Tekin, M., Stratton, R. F., Sujansky, E., Bale, S. J., & Muenke, M. (2002) · Human Genetics · doi:10.1007/s00439-002-0695-5 · Cited by 244
Research works printed but not linked: 1
- Tranebjærg, 2000, Polycystic lipomembranous osteodysplasia, Tidsskr Nor Laegeforen, 120, 3196
Cited by
Items 101–200 of 694
The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk
Deming, Y., Filipello, F., Cignarella, F., Cantoni, C., Hsu, S., Mikesell, R., Li, Z., Del-Aguila, J. L., Dube, U., Farias, F. G., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau2291 · Cited by 271
“However, the risk variants in TYROBP are all rare (59, 60), and although there are variants in ADAM10 known to affect the function or expression of ADAM10, these variants also occur infrequently (61).”
Application of Metabolomics in Alzheimer’s Disease
Wilkins, J. M., & Trushina, E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2017.00719 · Cited by 268
“The protein triggering receptor expressed on myeloid cells 2 (TREM2) is a cell surface receptor known for its role in immune signaling (183).”
BackgroundTREM2 Variant p.R47H as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis
Cady, J., Koval, E. D., Benitez, B. A., Zaidman, C., Jockel-Balsarotti, J., Allred, P., Baloh, R. H., Ravits, J., Simpson, E., Appel, S. H., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6237 · Cited by 262
“0) [4-108] r = −0.”
Neuroinflammation: Ways in Which the Immune System Affects the Brain
Ransohoff, R. M., Schafer, D., Vincent, A., Blachère, N. E., & Bar-Or, A. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0385-3 · Cited by 243
“The role of microglia in brain development and function was suggested by investigation of Nasu-Hakola disease, a rare genetic dementing leukoencephalopathy caused by homozygous deficiency of triggering receptor on myeloid cells 2 (TREM2), which is only expressed in the CNS on microglia [15].”
Microglia and aging: the role of the TREM2-DAP12 and CX3CL1-CX3CR1 axes
Mecca, C., Giambanco, I., Donato, R., & Arcuri, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010318 · Cited by 258
“NHD is a rare intractable autosomal recessive leukodystrophy [82] caused by genetic mutations of either TREM2 or DAP12 genes [75].”
BackgroundThe genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2
Klünemann, H. H., Ridha, B. H., Magy, L., Wherrett, J. R., Hemelsoet, D. M., Keen, R. W., De Bleecker, J. L., Rossor, M. N., Marienhagen, J., Klein, H. E., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000160304.00003.ca · Cited by 254
Self-citationTREM2 and Neurodegenerative Disease
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1306509 · Cited by 254
The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease
Cheng-Hathaway, P. J., Reed-Geaghan, E. G., Jay, T. R., Casali, B. T., Bemiller, S. M., Puntambekar, S. S., von Saucken, V. E., Williams, R. Y., Karlo, J. C., Moutinho, M., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0262-8 · Cited by 252
“Furthermore, homozygous TREM2 variants cause Nasu-Hakola disease, which is characterized by extensive white matter loss and frontotemporal-like dementia [6].”
BackgroundImpact of TREM2R47H variant on tau pathology–induced gliosis and neurodegeneration
Gratuze, M., Leyns, C. E. G., Sauerbeck, A. D., St-Pierre, M.-K., Xiong, M., Kim, N., Serrano, J. R., Tremblay, M.-È., Kummer, T. T., Colonna, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138179 · Cited by 252
Neumann, H., & Takahashi, K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.032 · Cited by 249
Impaired Synaptic Function in the Microglial KARAP/DAP12-Deficient Mouse
Roumier, A., Béchade, C., Poncer, J.-C., Smalla, K.-H., Tomasello, E., Vivier, E., Gundelfinger, E. D., Triller, A., & Bessis, A. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2251-04.2004 · Cited by 229
“A strong demyelinization is observed in PLOSL patients (Paloneva et al., 2001) as well as in the thalamus of KARAP/DAP12deficient adult mice (Kaifu et al., 2003).”
BackgroundInfluentialImpaired Differentiation of Osteoclasts in TREM-2–deficient Individuals
Cella, M., Buonsanti, C., Strader, C., Kondo, T., Salmaggi, A., & Colonna, M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022220 · Cited by 242
“Rare TREM-2– and DAP12-deficient individuals have been recently identified (7, 8).”
BackgroundSelf-citationRole of ITAM‐containing adapter proteins and their receptors in the immune system and bone
Humphrey, M. B., Lanier, L. L., & Nakamura, M. C. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00325.x · Cited by 241
“In PLOSL patients, large bony cysts filled with lipid are present in skeletal regions that have a high percentage of cancellous bones, including the carpals, tarsals, wrists, and ankles (82, 84, 94).”
BackgroundThe role of TREM2 in Alzheimer's disease and other neurodegenerative disorders
Carmona, S., Zahs, K., Wu, E., Dakin, K., Bras, J., & Guerreiro, R. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30232-1 · Cited by 244
Kober, D. L., Alexander-Brett, J. M., Karch, C. M., Cruchaga, C., Colonna, M., Holtzman, M. J., & Brett, T. J. (2016) · eLife · doi:10.7554/elife.20391 · Cited by 238
Sayed, F. A., Telpoukhovskaia, M., Kodama, L., Li, Y., Zhou, Y., Le, D., Hauduc, A., Ludwig, C., Gao, F., Clelland, C., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811411115 · Cited by 229
“Indeed, complete loss of TREM2 in humans results in Nasu–Hakola disease (31), which could be driven by mechanisms that are distinct from those of AD.”
BackgroundMicroglia in Alzheimer’s Disease: Activated, Dysfunctional or Degenerative
Navarro, V., Sanchez-Mejias, E., Jimenez, S., Muñoz-Castro, C., Sanchez-Varo, R., Davila, J. C., Vizuete, M., Gutierrez, A., & Vitorica, J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00140 · Cited by 229
“…key genes for the microglial survival and/or proliferation (such as CSF1R or TREM2) are associated with rare hereditary neurodegenerative diseases, such as adult-onset leukoencephalopathy with axonal spheroids or Nasu-Hakola disease (respectively) (Paloneva et al., 2000, 2002; Chitu et al., 2016).”
BackgroundUntangling Genetic Risk for Alzheimer’s Disease
Pimenova, A. A., Raj, T., & Goate, A. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.014 · Cited by 223
“frontotemporal dementia-like syndrome (123), making TREM2 a candidate gene for targeted sequencing in AD patients.”
BackgroundTREM2 and the neuroimmunology of Alzheimer's disease
Hickman, S. E., & El Khoury, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.021 · Cited by 221
“While this remains a small possibility based on what we know from patients with Nasu–Hakola disease [45] it is crucial to determine whether the effects of TREM2 variants are due to either loss-of-function, gain-of-function or a novel yet to be defined pathway.”
BackgroundCross-regulation of signaling by ITAM-associated receptors
Ivashkiv, L. B. (2009) · Nature Immunology · doi:10.1038/ni.1706 · Cited by 215
“DAP12 and TREM-2 are implicated in bone remodeling and osteoclastogenesis in human”
TREM2, microglia, and Alzheimer’s disease.
Qin, Q., Teng, Z., Liu, C., Li, Q., Yin, Y., & Tang, Y. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111438 · Cited by 219
Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan
Tay, T. L., Béchade, C., D’Andrea, I., St-Pierre, M.-K., Henry, M. S., Roumier, A., & Tremblay, M.-E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00421 · Cited by 216
“…by recessive gene Frontiers in Molecular Neuroscience | www.frontiersin.org 5 January 2018 | Volume 10 | Article 421 mutations of DAP12 (TYRO Protein Tyrosine Kinase Binding Protein) or TREM2 (Triggering Receptor Expressed On Myeloid Cells 2, Paloneva et al., 2000, 2002; Bianchin et al., 2004).”
BackgroundBauman, M. (2006) · Johns Hopkins University Press eBooks · doi:10.1353/book.3225 · Cited by 214
Liu, W., Taso, O., Wang, R., Bayram, S., Graham, A. C., Garcia-Reitboeck, P., Mallach, A., Andrews, W. D., Piers, T. M., Botia, J. A., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa209 · Cited by 214
“In the brain, TREM2 is predominantly expressed by microglia (Paloneva et al. 2002; Schmid et al. 2002; Takahashi et al. 2005; Wang et al. 2016).”
BackgroundMicroglia are required for protection against lethal coronavirus encephalitis in mice
Wheeler, D. L., Sariol, A., Meyerholz, D. K., & Perlman, S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97229 · Cited by 212
OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice
Barrow, A. D., Raynal, N., Andersen, T. L., Slatter, D. A., Bihan, D., Pugh, N., Cella, M., Kim, T., Rho, J., Negishi-Koga, T., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45913 · Cited by 207
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease
Mass, E., Jacome-Galarza, C. E., Blank, T., Lazarov, T., Durham, B. H., Ozkaya, N., Pastore, A., Schwabenland, M., Chung, Y. R., Rosenblum, M. K., et al. (2017) · Nature · doi:10.1038/nature23672 · Cited by 210
Lill, C. M., Rengmark, A., Pihlstrøm, L., Fogh, I., Shatunov, A., Sleiman, P. M., Wang, L., Liu, T., Lassen, C. F., Meissner, E., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.12.009 · Cited by 205
“TREM2 was earlier reported to harbor autosomal-recessive mutations causing NasuHakola disease [8], a neurodegenerative disorder characterized by progressive presenile dementia and cystic bone lesions, and underlying familial FTLD [9].”
Li, R.-Y., Qin, Q., Yang, H.-C., Wang, Y.-Y., Mi, Y.-X., Yin, Y.-S., Wang, M., Yu, C.-J., & Tang, Y. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00542-y · Cited by 204
“At the anatomical level, TREM2 is highly expressed in the corpus callosum and basal ganglia [42], while at the cellular level, TREM2 is selectively expressed in microglia [26].”
BackgroundThe Role of APOE and TREM2 in Alzheimer′s Disease—Current Understanding and Perspectives
Wolfe, C. M., Fitz, N. F., Nam, K. N., Lefterov, I., & Koldamova, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010081 · Cited by 187
“Rare biallelic mutations that result in loss of function of TREM2 cause Nasu–Hakola disease [67] (NHD) and in some cases Frontotemporal dementia (FTD) [68,85].”
BackgroundVoß, E. V., Škuljec, J., Gudi, V., Skripuletz, T., Pul, R., Trebst, C., & Stangel, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.008 · Cited by 202
“, 2001), that is most probably caused by an impaired phagocytic function of microglia (Paloneva et al., 2002).”
BackgroundCommon signalling pathways in macrophage and osteoclast multinucleation
Pereira, M., Petretto, E., Gordon, S., Bassett, J. H. D., Williams, G. R., & Behmoaras, J. (2018) · Journal of Cell Science · doi:10.1242/jcs.216267 · Cited by 189
Microglia regulate synaptic development and plasticity
Andoh, M., & Koyama, R. (2021) · Developmental Neurobiology · doi:10.1002/dneu.22814 · Cited by 184
“TAR DNA- binding protein of 43 kDa (TDP- 43) is a major constituent protein of ubiquitin- positive inclusions found in neurons and glial cells in the brains of ALS and frontotemporal lobar degeneration (FTLD) patients.”
BackgroundFunctional Studies of Missense TREM2 Mutations in Human Stem Cell-Derived Microglia
Brownjohn, P. W., Smith, J., Solanki, R., Lohmann, E., Houlden, H., Hardy, J., Dietmann, S., & Livesey, F. J. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.03.003 · Cited by 193
“, 2010; Ransohoff, 2016), with variants or mutations in microglia-expressed genes linked directly to disease in some cases (Malik et al., 2015; Paloneva et al., 2002; Sims et al., 2017).”
BackgroundThurgur, H., & Pinteaux, E. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.06.046 · Cited by 176
TREM2 dependent and independent functions of microglia in Alzheimer’s disease
Hou, J., Chen, Y., Grajales-Reyes, G., & Colonna, M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00588-y · Cited by 191
“Rare variants of TREM2 that cause complete lack of TREM2 expression were first reported in Nasu-Hakola disease (NHD), an autosomal recessive early-onset dementia with bone cysts [135].”
BackgroundGenomic variants, genes, and pathways of Alzheimer's disease: An overview
Naj, A. C., Schellenberg, G. D., & for the Alzheimer's Disease Genetics Consortium (ADGC) (2017) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32499 · Cited by 179
“Mutations in TREM2 have been previously implicated in Nasu Hakola disease [Paloneva et al., 2002] and early-onset dementia without bone cysts [Chouery et al., 2008].”
BackgroundTargeting microglia for the treatment of Alzheimer’s Disease
Wes, P. D., Sayed, F. A., Bard, F., & Gan, L. (2016) · Glia · doi:10.1002/glia.22988 · Cited by 185
“Homozygous loss-of-function mutations in TREM2 cause a severe form of dementia with bone cystic lesions known as Nasu-Hakola disease (Bianchin et al., 2004; Paloneva et al., 2002).”
BackgroundCuyvers, E., Bettens, K., Philtjens, S., Van Langenhove, T., Gijselinck, I., van der Zee, J., Engelborghs, S., Vandenbulcke, M., Van Dongen, J., Geerts, N., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.009 · Cited by 182
“This complex is involved in the immune response and activation of macrophages/microglia and dendritic cells, resulting in phagocytosis and elevated short-term production of reactive oxygen species (Neumann and daly, 2012; Paloneva et al., 2002).”
BackgroundAllcock, R. J. N., Barrow, A. D., Forbes, S., Beck, S., & Trowsdale, J. (2003) · European Journal of Immunology · doi:10.1002/immu.200310033 · Cited by 173
Protein-Protein Interactions in the Membrane: Sequence, Structural, and Biological Motifs
Moore, D. T., Berger, B. W., & DeGrado, W. F. (2008) · Structure · doi:10.1016/j.str.2008.05.007 · Cited by 178
“The importance of these interactions is illustrated by a Lys to Asn mutation in the TREM-2 receptor that blocks assembly with the DAP12 adaptor protein and results in NasuHakola disease (Paloneva et al., 2002).”
BackgroundNebert, D. W., Zhang, G., & Vesell, E. S. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530801952864 · Cited by 181
Insights into TREM2 biology by network analysis of human brain gene expression data
Forabosco, P., Ramasamy, A., Trabzuni, D., Walker, R., Smith, C., Bras, J., Levine, A. P., Hardy, J., Pocock, J. M., Guerreiro, R., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.001 · Cited by 180
“…view is the fact that homozygous loss-offunction mutations in either TREM2 or TYROBP result in NasueHakola disease (Online Mendelian Inheritance in Man number 605086), a rare disease characterized by painful bone cysts, psychotic symptoms, and progressive presenile dementia (Paloneva et al., 2002).”
TREM2 and β-Catenin Regulate Bone Homeostasis by Controlling the Rate of Osteoclastogenesis
Otero, K., Shinohara, M., Zhao, H., Cella, M., Gilfillan, S., Colucci, A., Faccio, R., Ross, F. P., Teitelbaum, S. L., Takayanagi, H., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102836 · Cited by 171
“In humans, inactivating mutations of either TREM2 or DAP12 result in a disorder known as Nasu–Hakola disease (NHD) or polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (19, 20).”
BackgroundOosterhof, N., Kuil, L. E., van der Linde, H. C., Burm, S. M., Berdowski, W., van Ijcken, W. F. J., van Swieten, J. C., Hol, E. M., Verheijen, M. H. G., & van Ham, T. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.113 · Cited by 178
Variant TREM2 as Risk Factor for Alzheimer's Disease
Neumann, H., & Daly, M. J. (2013) · New England Journal of Medicine · doi:10.1056/nejme1213157 · Cited by 177
From syndrome families to functional genomics
Brunner, H. G., & van Driel, M. A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1383 · Cited by 175
“Mutations in a gene that encodes a membrane receptor on natural-killer and myeloid cells, and in the gene that encodes a ligand for this receptor, each resulted in this disease phenotyp”
BackgroundSoluble phospho-tau from Alzheimer’s disease hippocampus drives microglial degeneration
Sanchez-Mejias, E., Navarro, V., Jimenez, S., Sanchez-Mico, M., Sanchez-Varo, R., Nuñez-Diaz, C., Trujillo-Estrada, L., Davila, J. C., Vizuete, M., Gutierrez, A., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1630-5 · Cited by 175
“In this sense, deficiencies in key genes for microglial survival and/or proliferation (such as CSF1R or TREM2) are associated with rare hereditary neurodegenerative diseases, such as adult-onset leukoencephalopathy with axonal spheroids or Nasu–Hakola disease (respectively) [6, 38, 39].”
BackgroundHeterozygous TREM2 mutations in frontotemporal dementia
Borroni, B., Ferrari, F., Galimberti, D., Nacmias, B., Barone, C., Bagnoli, S., Fenoglio, C., Piaceri, I., Archetti, S., Bonvicini, C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.017 · Cited by 173
“Q33X and T66M mutations have previously been demonstrated to cause Nasu-Hakola disease in the homozygous state (Paloneva et al., 2000, 2002), and the heterozygous R47H mutation has been associated with AD risk (Guerreiro et al., 2013b; Jonsson et al., 2013).”
BackgroundCerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
McGrowder, D. A., Miller, F., Vaz, K., Nwokocha, C., Wilson-Clarke, C., Anderson-Cross, M., Brown, J., Anderson-Jackson, L., Williams, L., Latore, L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11020215 · Cited by 167
Genetics of Alzheimer's Disease
Guerreiro, R., & Hardy, J. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0295-9 · Cited by 155
“TREM2 had previously been associated with Nasu-Hakola disease, a rare autosomal recessive form of dementia presenting with bone cysts [24].”
BackgroundTREM2 in CNS homeostasis and neurodegenerative disease
Painter, M. M., Atagi, Y., Liu, C.-C., Rademakers, R., Xu, H., Fryer, J. D., & Bu, G. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0040-9 · Cited by 169
“erative phenotypes including NHD/PLOSL [10, 11], FTD”
BackgroundZhong, L., Sheng, X., Wang, W., Li, Y., Zhuo, R., Wang, K., Zhang, L., Hu, D.-D., Hong, Y., Chen, L., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.016 · Cited by 168
Infantile Malignant, Autosomal Recessive Osteopetrosis: The Rich and The Poor
Villa, A., Guerrini, M. M., Cassani, B., Pangrazio, A., & Sobacchi, C. (2009) · Calcified Tissue International · doi:10.1007/s00223-008-9196-4 · Cited by 166
“Other genes, such as c-fms (the receptor for M-CSF), DAP12, and TREM2, have been shown to cause either osteopetrosis associated with other defects in mouse [74] or specific bone diseases different from pure osteopetrosis in humans [75, 76].”
BackgroundSessa, G., Podini, P., Mariani, M., Meroni, A., Spreafico, R., Sinigaglia, F., Colonna, M., Panina, P., & Meldolesi, J. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03729.x · Cited by 165
“…white matter lesions observed in PLOSL patients and in mice lacking functional DAP12, i.e. leukodystrophy with sclerosing leukoencephalopathy (Paloneva et al., 2002) and demyelinization (Kaifu et al., 2003), could be due not to primary defect(s) of the myelinsynthesizing cells but to…”
BackgroundInfluentialKARAP/DAP12/TYROBP: three names and a multiplicity of biological functions
Tomasello, E., & Vivier, E. (2005) · European Journal of Immunology · doi:10.1002/eji.200425932 · Cited by 163
TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function
Humphrey, M. B., Daws, M. R., Spusta, S. C., Niemi, E. C., Torchia, J. A., Lanier, L. L., Seaman, W. E., & Nakamura, M. C. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051016 · Cited by 162
Garcia-Reitboeck, P., Phillips, A., Piers, T. M., Villegas-Llerena, C., Butler, M., Mallach, A., Rodrigues, C., Arber, C. E., Heslegrave, A., Zetterberg, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.094 · Cited by 162
“NHD is a rare autosomal-recessive early-onset dementia characterized by behavioral changes and cognitive decline, with or without pathological bone fractures (Guerreiro et al., 2013b; Paloneva et al., 2002).”
BackgroundLate-Onset Alzheimer’s Disease Genes and the Potentially Implicated Pathways
Rosenthal, S. L., & Kamboh, M. I. (2014) · Current Genetic Medicine Reports · doi:10.1007/s40142-014-0034-x · Cited by 153
“Previously, mutations in TREM2 have been associated with Nasu-Hakola disease (aka polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, PLOSL) [120, 121].”
BackgroundJi, J.-D., Park-Min, K.-H., Shen, Z., Fajardo, R. J., Goldring, S. R., McHugh, K. P., & Ivashkiv, L. B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900072 · Cited by 157
“TREM-2 has been reported to play an important role in human osteoclastogenesis in patients with TREM-2 loss-of-function mutations that manifest as Nasu-Hakola disease (29, 31, 32), and we have recently confirmed a role for TREM-2 in human osteoclastogenesis using RNA interference (41).”
BackgroundGenetics ignite focus on microglial inflammation in Alzheimer’s disease
Malik, M., Parikh, I., Vasquez, J. B., Smith, C., Tai, L., Bu, G., LaDu, M. J., Fardo, D. W., Rebeck, G. W., & Estus, S. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0048-1 · Cited by 161
“cysts [24, 39–42].”
Long, H., Simmons, A., Mayorga, A., Burgess, B., Nguyen, T., Budda, B., Rychkova, A., Rhinn, H., Tassi, I., Ward, M., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01599-1 · Cited by 124
“Homozygous loss-of-function mutations in TREM2 , or its signaling co-receptor gene TYROBP , cause Nasu-Hakola disease, which is characterized by early-onset dementia [17].”
BackgroundOhgidani, M., Kato, T. A., Setoyama, D., Sagata, N., Hashimoto, R., Shigenobu, K., Yoshida, T., Hayakawa, K., Shimokawa, N., Miura, D., et al. (2014) · Scientific Reports · doi:10.1038/srep04957 · Cited by 146
High‐affinity interactions and signal transduction between Aβ oligomers and TREM 2
Lessard, C. B., Malnik, S. L., Zhou, Y., Ladd, T. B., Cruz, P. E., Ran, Y., Mahan, T. E., Chakrabaty, P., Holtzman, D. M., Ulrich, J. D., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809027 · Cited by 154
“Numerous studies of the PLOSL-associated TREM2 variants suggest that these variants are loss of function altering maturation and cell-surface expression of TREM2 (Paloneva et al, 2001, 2002).”
BackgroundMicroglia: Key players in neurodevelopment and neuronal plasticity
Sominsky, L., Luca, S. N. D., & Spencer, S. J. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.11.012 · Cited by 163
Lue, L., Schmitz, C. T., Serrano, G., Sue, L. I., Beach, T. G., & Walker, D. G. (2015) · Brain Pathology · doi:10.1111/bpa.12190 · Cited by 154
“This was first established in a pre-senile dementia in patients with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), also known as Nasu Hakola disease (34, 35).”
BackgroundMcKenzie, A. T., Moyon, S., Wang, M., Katsyv, I., Song, W.-M., Zhou, X., Dammer, E. B., Duong, D. M., Aaker, J., Zhao, Y., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0219-3 · Cited by 154
“For example,TREM2, an established AD risk factor that is primarily expressed in immune cells [87, 88], is also the causative gene of Nasu-Hakola disease, an earlyonset subcortical dementia that presents with white matter demyelination [89].”
BackgroundTREM2 Function in Alzheimer’s Disease and Neurodegeneration
Ulrich, J. D., & Holtzman, D. M. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00313 · Cited by 154
Bianchin, M. M., Capella, H. M., Chaves, D. L., Steindel, M., Grisard, E. C., Ganev, G. G., da Silva, J. P., Neto, E. S., Poffo, M. A., Walz, R., et al. (2004) · Cellular and Molecular Neurobiology · doi:10.1023/b:cemn.0000012721.08168.ee · Cited by 168
“Recently, a similar PLOSL phenotype was associated with different mutations in the DAP12 (also known as TYROBP) gene or in the TREM2 gene, demonstrating the genetic heterogeneity of this disease (Paloneva et al., 2002).”
BackgroundInfluentialSelf-citationThe surface‐exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor
Stefano, L., Racchetti, G., Bianco, F., Passini, N., Gupta, R. S., Bordignon, P. P., & Meldolesi, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06130.x · Cited by 152
“…al. 2006; Colonna et al. 2007); the brain exhibits an ample spectrum of lesions including atrophy, extensive leukodystrophy, axonal loss and glyosis, accompanied by severe neurological and psychiatric symptoms, i.e. convulsions and an early onset, progressive dementia (Paloneva et al. 2000, 2002).”
BackgroundTREM2 is associated with increased risk for Alzheimer’s disease in African Americans
Jin, S. C., Carrasquillo, M. M., Benitez, B. A., Skorupa, T., Carrell, D., Patel, D., Lincoln, S., Krishnan, S., Kachadoorian, M., Reitz, C., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0016-9 · Cited by 153
“called Nasu-Hakola disease) characterized by progressive early-onset dementia and bone lesions leading to fractures [3-5].”
BackgroundThe Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer’s Disease
Kloske, C. M., & Wilcock, D. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00754 · Cited by 152
“Individuals homozygous for mutations in TREM2 develop a rare disorder characterized by bone fractures and presenile dementia called Nasu-Hakola disease (81, 82).”
BackgroundLynch, D. S., Wade, C., de Paiva, A. R. B., John, N. A., Kinsella, J. A., Merwick, Á., Ahmed, R. M., Warren, J. D., Mummery, C. J., Schott, J. M., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-319481 · Cited by 155
Giraldo, M., Lopera, F., Siniard, A. L., Corneveaux, J. J., Schrauwen, I., Carvajal, J., Muñoz, C., Ramirez-Restrepo, M., Gaiteri, C., Myers, A. J., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.02.016 · Cited by 147
“1), which is characterized by cystic-like lesions of the bone and brain demyelination that lead to fractures and presenile dementia (Paloneva et al., 2002).”
BackgroundInfluentialRole of microglia in neuronal degeneration and regeneration
Walter, L. M., & Neumann, H. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0180-5 · Cited by 167
“The phenotype of PLOSL only affects two organ systems, bone and brain, leading to bone cysts and presenile dementia.”
BackgroundReview: neuropathology of non-tau frontotemporal lobar degeneration
Neumann, M., & Mackenzie, I. R. A. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12526 · Cited by 144
TREM2 promotes Aβ phagocytosis by upregulating C/EBPα-dependent CD36 expression in microglia
Kim, S.-M., Mun, B.-R., Lee, S.-J., Joh, Y., Lee, H.-Y., Ji, K.-Y., Choi, H.-R., Lee, E.-H., Kim, E.-M., Jang, J.-H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11634-x · Cited by 143
Konishi, H., Kobayashi, M., Kunisawa, T., Imai, K., Sayo, A., Malissen, B., Crocker, P. R., Sato, K., & Kiyama, H. (2017) · Glia · doi:10.1002/glia.23204 · Cited by 137
“Besides neuropathic pain, TREM2/DAP12-mediated microglial activation is also pivotal for pathogenesis of Alzheimer’s disease both in humans and in mouse models of the disease (Guerreiro et al., 2013; Jonsson et al., 2013; Paloneva et al., 2000, 2002; Wang et al., 2015; Zhang et al., 2013).”
BackgroundThe role of microglia in human disease: therapeutic tool or target?
Cartier, N., Lewis, C.-A., Zhang, R., & Rossi, F. M. V. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1330-y · Cited by 136
“RTT combines neuronal damage to non-cell-autonomous glial dysfunction.”
BackgroundInfluentialHu, X., Liou, A. K. F., Leak, R. K., Xu, M., An, C., Suenaga, J., Shi, Y., Gao, Y., Zheng, P., & Chen, J. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.06.002 · Cited by 131
Korvatska, O., Leverenz, J. B., Jayadev, S., McMillan, P., Kurtz, I., Guo, X., Rumbaugh, M., Matsushita, M., Girirajan, S., Dorschner, M. O., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0979 · Cited by 137
Self-citationThe Finnish disease heritage III: the individual diseases
Norio, R. (2003) · Human Genetics · doi:10.1007/s00439-002-0877-1 · Cited by 163
Soluble TREM2: Innocent bystander or active player in neurological diseases?
Filipello, F., Goldsbury, C., You, S. F., Locca, A., Karch, C. M., & Piccio, L. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105630 · Cited by 134
Microglia in Alzheimer’s Disease in the Context of Tau Pathology
Perea, J. R., Bolós, M., & Avila, J. (2020) · Biomolecules · doi:10.3390/biom10101439 · Cited by 123
“However, its activity should be partially suppressed in advanced stages since complete abolishment could lead to Nasu–Hakola disease, which is characterized mainly by bone lesions [214] (Figure 2).”
BackgroundZhong, L., Chen, X.-F., Zhang, Z.-L., Wang, Z., Shi, X.-Z., Xu, K., Zhang, Y.-W., Xu, H., & Bu, G. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645986 · Cited by 133
“In this regard, it is interesting to note that a mutation within the transmembrane domain of TREM2 (K186N), which potentially disrupts the interaction between TREM2 and DAP12, is associated with Nasu-Hakola disease (44).”
BackgroundPeng, J., Liu, Y., Umpierre, A. D., Xie, M., Tian, D.-S., Richardson, J. R., & Wu, L.-J. (2019) · Molecular Brain · doi:10.1186/s13041-019-0492-x · Cited by 130
A TREM family member, TLT-1, is found exclusively in the α-granules of megakaryocytes and platelets
Washington, A. V., Schubert, R. L., Quigley, L., Disipio, T., Feltz, R., Cho, E. H., & McVicar, D. W. (2004) · Blood · doi:10.1182/blood-2004-01-0315 · Cited by 126
Microglia-Mediated Neuroprotection, TREM2, and Alzheimer’s Disease: Evidence From Optical Imaging
Condello, C., Yuan, P., & Grutzendler, J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.007 · Cited by 131
“However, human TREM2 variants appear to also modestly increase the risk of non–Ab-based disorders such as amyotrophic lateral sclerosis, frontotemporal dementia (66–70), and Nasu-Hakola disease in homozygous mutants (53,71).”
Differential contribution of microglia and monocytes in neurodegenerative diseases
Baufeld, C., O’Loughlin, E., Calcagno, N., Madore, C., & Butovsky, O. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1795-7 · Cited by 123
“Homozygous mutations in TREM2, a myeloid cell-sur- face receptor which is also implicated in AD, lead to demyelination and early onset dementia in humans (Palo- neva et al. 2002).”
BackgroundPhenotypic Heterogeneity of Monogenic Frontotemporal Dementia
Benussi, A., Padovani, A., & Borroni, B. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00171 · Cited by 123
Reiner, A. P., Beleza, S. S., Franceschini, N., Auer, P. L., Robinson, J. G., Kooperberg, C. L., Peters, U., & Tang, H. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.07.023 · Cited by 140
Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances
Randolph, G. J., Sánchez‐Schmitz, G., & Angeli, V. (2004) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0168-0 · Cited by 146
“In humans, TREM-2 is selectively expressed in lymph nodes and is not observed, for example, in spleen [57].”
BackgroundFerrero, G., Mahony, C. B., Dupuis, E., Yvernogeau, L., Di Ruggiero, E., Miserocchi, M., Caron, M., Robin, C., Traver, D., Bertrand, J. Y., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.066 · Cited by 119
“Elegant live-imaging studies in mouse (Davalos et al., 2005; Nimmerjahn et al., 2005) and zebrafish (Li et al., 2012; Peri and N € usslein-Volhard, 2008; Sieger et al., 2012) have shown that MG constantly survey their surroundings through highly motile cellularprocesses and quickly react to…”
BackgroundThe Signaling Adapter Protein DAP12 Regulates Multinucleation During Osteoclast Development
Humphrey, M. B., Ogasawara, K., Yao, W., Spusta, S. C., Daws, M. R., Lane, N. E., Lanier, L. L., & Nakamura, M. C. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301234 · Cited by 123
“In humans with PLOSL, large bony cysts filled with lipid are present((7,8,17)) in skeletal regions that have a high percentage of cancellous bones including the carpals, tarsals, wrists, and ankles.”
BackgroundPark‐Min, K., Ji, J.-D., Antoniv, T. T., Reid, A. C., Silver, R. B., Humphrey, M. B., Nakamura, M. C., & Ivashkiv, L. B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804165 · Cited by 130
Pathological role of osteoclast costimulation in arthritis-induced bone loss
Ochi, S., Shinohara, M., Sato, K., Gober, H.-J., Koga, T., Kodama, T., Takai, T., Miyasaka, N., & Takayanagi, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701971104 · Cited by 119
Immunoreceptor-like signaling by β2 and β3 integrins
Jakus, Z., Fodor, S., Abram, C. L., Lowell, C. A., & Mócsai, A. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.09.001 · Cited by 137
Mutations in TREM2 lead to pure early-onset dementia without bone cysts
Chouery, E., Delague, V., Bergougnoux, A., Koussa, S., Serre, J.-L., & Mégarbané, A. (2008) · Human Mutation · doi:10.1002/humu.20836 · Cited by 124
“DAP12 named also TYROBP (TYRO protein tyrosine kinase binding protein; MIM# 604142) and TREM2 (triggering receptors expressed on myeloid cells-2; MIM# 605086) are responsible for PLOSL (Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy; MIM# 221770), an autosomal recessive disease characteri…”
BackgroundFani Maleki, A., & Rivest, S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00355 · Cited by 119
“Moreover, a rare mutation of human TREM2 (R47H) determines a high risk for developing AD and Nasu-Hakola disease, a disorder characterized by dementia, and amyloid plaque deposition is caused by genetic mutation of TREM2 or DAP12 genes (Paloneva et al., 2002).”
BackgroundSlattery, C. F., Beck, J. A., Harper, L., Adamson, G., Abdi, Z., Uphill, J., Campbell, T., Druyeh, R., Mahoney, C. J., Rohrer, J. D., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.05.1751 · Cited by 119
Metadata
- Authors
- Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., Tranebjærg, L., Konttinen, Y., & Peltonen, L.
- Affiliations
- University of Helsinki (FI)
- University of California, Los Angeles (US)
- Umeå University (SE)
- University of Washington (US)
- Hospital Universitario La Paz (ES)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Bispebjerg Hospital (DK)
- Helsinki University Hospital (FI)
- Corresponding author
- Peltonen, Leena
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 71
- Issue
- 3
- Pages
- 656-662
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC379202
- OpenAlex
- W2014200126
- Cited by
- 683
- References
- 29
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 27 · 2023: 35 · 2022: 37 · 2021: 48 · 2020: 47 · 2019: 34 · 2018: 54 · 2017: 53 · 2016: 38 · 2015: 42 · 2014: 29 · 2013: 28 · 2012: 11
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 3974 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Lastentautien Tutkimussäätiö
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Nasu-Hakola disease, TREM2, TYROBP, DAP12, receptor signaling complex, genetic heterogeneity, progressive dementia, bone cysts, recessive inheritance
- MeSH terms
- Triggering Receptor Expressed on Myeloid Cells-1, Actins, Female, Haplotypes, Humans, Male, Membrane Glycoproteins, Membrane Proteins, Molecular Sequence Data, Mutation, Pedigree, Phenotype, Receptors, Immunologic, RNA, Messenger, Signal Transduction, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Protein Subunits, Macromolecular Substances, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.